171 related articles for article (PubMed ID: 38372904)
21. The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2.
Alanin MC; Klausen C; Caye-Thomasen P; Thomsen C; Fugleholm K; Poulsgaard L; Lassen U; Mau-Sorensen M; Hofland KF
Eur Arch Otorhinolaryngol; 2015 Dec; 272(12):3627-33. PubMed ID: 25421643
[TBL] [Abstract][Full Text] [Related]
22. Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2.
Mautner VF; Nguyen R; Kutta H; Fuensterer C; Bokemeyer C; Hagel C; Friedrich RE; Panse J
Neuro Oncol; 2010 Jan; 12(1):14-8. PubMed ID: 20150363
[TBL] [Abstract][Full Text] [Related]
23. Effect of lapatinib on meningioma growth in adults with neurofibromatosis type 2.
Osorio DS; Hu J; Mitchell C; Allen JC; Stanek J; Hagiwara M; Karajannis MA
J Neurooncol; 2018 Sep; 139(3):749-755. PubMed ID: 29948766
[TBL] [Abstract][Full Text] [Related]
24. Managing NF2-associated vestibular schwannomas in children and young adults: review of an institutional series regarding effects of surgery and bevacizumab on growth rates, tumor volume, and hearing quality.
Gugel I; Zipfel J; Hartjen P; Kluwe L; Tatagiba M; Mautner VF; Schuhmann MU
Childs Nerv Syst; 2020 Oct; 36(10):2471-2480. PubMed ID: 32548671
[TBL] [Abstract][Full Text] [Related]
25. Concordance of bilateral vestibular schwannoma growth and hearing changes in neurofibromatosis 2: neurofibromatosis 2 natural history consortium.
Fisher LM; Doherty JK; Lev MH; Slattery WH
Otol Neurotol; 2009 Sep; 30(6):835-41. PubMed ID: 19704365
[TBL] [Abstract][Full Text] [Related]
26. Improvement in Patient-reported Hearing After Treatment With Bevacizumab in People With Neurofibromatosis Type 2.
Huang V; Bergner AL; Halpin C; Merker VL; Sheridan MR; Widemann BC; Blakeley JO; Plotkin SR
Otol Neurotol; 2018 Jun; 39(5):632-638. PubMed ID: 29649040
[TBL] [Abstract][Full Text] [Related]
27. Long-term follow-up studies of Gamma Knife surgery for patients with neurofibromatosis Type 2.
Sun S; Liu A
J Neurosurg; 2014 Dec; 121 Suppl():143-9. PubMed ID: 25434947
[TBL] [Abstract][Full Text] [Related]
28. Phase II trial of icotinib in adult patients with neurofibromatosis type 2 and progressive vestibular schwannoma.
Zhao F; Li SW; Zhang S; Li P; Zhao C; Zhao XB; Wang CH; Zhang J; Wang B; Liu PN
J Neurosurg; 2023 Jun; 138(6):1680-1687. PubMed ID: 36272122
[TBL] [Abstract][Full Text] [Related]
29. Reliability and toxicity of bevacizumab for neurofibromatosis type 2-related vestibular schwannomas: A systematic review and meta-analysis.
Shi J; Lu D; Gu R; Sun H; Yu L; Pan R; Zhang Y
Am J Otolaryngol; 2021; 42(6):103148. PubMed ID: 34214711
[TBL] [Abstract][Full Text] [Related]
30. Proton Radiotherapy for Vestibular Schwannomas in Patients with NF2-Related Schwannomatosis: A Case Series.
Douwes JPJ; Koetsier KS; van Dam VS; Plotkin SR; Barker FG; Welling DB; Jansen JC; Hensen EF; Shih HA
Curr Oncol; 2023 Mar; 30(3):3473-3483. PubMed ID: 36975476
[TBL] [Abstract][Full Text] [Related]
31. Rationale and Design of BeatNF2 Trial: A Clinical Trial to Assess the Efficacy and Safety of Bevacizumab in Patients with Neurofibromatosis Type 2 Related Vestibular Schwannoma.
Fujii M; Kobayakawa M; Saito K; Inano A; Morita A; Hasegawa M; Mukasa A; Mitsuhara T; Goto T; Yamaguchi S; Tamiya T; Nakatomi H; Oya S; Takahashi F; Sato T; Bakhit M; On Behalf Of The BeatNF Trial Investigators
Curr Oncol; 2021 Jan; 28(1):726-739. PubMed ID: 33572546
[TBL] [Abstract][Full Text] [Related]
32. Unilateral vestibular schwannoma with other neurofibromatosis type 2-related tumors: clinical and molecular study of a unique phenotype.
Aghi M; Kluwe L; Webster MT; Jacoby LB; Barker FG; Ojemann RG; Mautner VF; MacCollin M
J Neurosurg; 2006 Feb; 104(2):201-7. PubMed ID: 16509493
[TBL] [Abstract][Full Text] [Related]
33. Stereotactic radiosurgery for neurofibromatosis 2-associated vestibular schwannomas: toward dose optimization for tumor control and functional outcomes.
Mallory GW; Pollock BE; Foote RL; Carlson ML; Driscoll CL; Link MJ
Neurosurgery; 2014 Mar; 74(3):292-300; discussion 300-1. PubMed ID: 24335819
[TBL] [Abstract][Full Text] [Related]
34. Advances in Targeted Therapy for Neurofibromatosis Type 2 (NF2)-Associated Vestibular Schwannomas.
Cumpston EC; Rhodes SD; Yates CW
Curr Oncol Rep; 2023 May; 25(5):531-537. PubMed ID: 36933171
[TBL] [Abstract][Full Text] [Related]
35. Natural history of vestibular schwannomas and hearing loss in NF2 patients.
Peyre M; Bernardeschi D; Sterkers O; Kalamarides M
Neurochirurgie; 2018 Nov; 64(5):342-347. PubMed ID: 26183546
[TBL] [Abstract][Full Text] [Related]
36. Cochlear Implant Outcomes between Patients with Sporadic and Neurofibromatosis Type 2-Associated Vestibular Schwannoma.
Dornhoffer JR; Haller T; Lohse CM; Driscoll CLW; Neff BA; Saoji A; Link MJ; Carlson ML
Otol Neurotol; 2023 Sep; 44(8):791-797. PubMed ID: 37464449
[TBL] [Abstract][Full Text] [Related]
37. Microsurgery for patients diagnosed with neurofibromatosis type 2 complicated by vestibular schwannomas: Clinical experience and strategy for treatments.
Chen LH; Zhang HT; Xu RX; Zhang L; Li WD; Sun K
Medicine (Baltimore); 2018 Apr; 97(17):e0270. PubMed ID: 29702972
[TBL] [Abstract][Full Text] [Related]
38. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2.
Plotkin SR; Stemmer-Rachamimov AO; Barker FG; Halpin C; Padera TP; Tyrrell A; Sorensen AG; Jain RK; di Tomaso E
N Engl J Med; 2009 Jul; 361(4):358-67. PubMed ID: 19587327
[TBL] [Abstract][Full Text] [Related]
39. AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas.
Bush ML; Oblinger J; Brendel V; Santarelli G; Huang J; Akhmametyeva EM; Burns SS; Wheeler J; Davis J; Yates CW; Chaudhury AR; Kulp S; Chen CS; Chang LS; Welling DB; Jacob A
Neuro Oncol; 2011 Sep; 13(9):983-99. PubMed ID: 21778190
[TBL] [Abstract][Full Text] [Related]
40. Stereotactic radiosurgery for vestibular schwannomas in neurofibromatosis type 2 patients: a systematic review and meta-analysis.
Tosi U; Maayan O; An A; Lavieri MET; Guadix SW; DeRosa AP; Christos PJ; Pannullo S; Stieg PE; Brandmaier A; Knisely JPS; Ramakrishna R
J Neurooncol; 2022 Jan; 156(2):431-441. PubMed ID: 35040021
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
